Amalia Ernestina Alfonsín1, Sofia Stephanie Escada2, Dana Kohan3, Melina Paula Valeo Chulvi4, María Lourdes Posadas Martínez5, María Adela Aguirre6, Elsa Mercedes Nucifora7. 1. Hospital Italiano de Buenos Aires - Imtib. amalia.alfonsin@hospitalitaliano.org.ar. 2. Hospital Italiano de Buenos Aires.. sofia.escada@hospitalitaliano.org.ar. 3. Hospital Italiano de Buenos Aires. dana.kohan@hiba.org.ar. 4. Hospital Italiano de Buenos Aires. melina.valeo@hiba.org.ar. 5. Hospital Italiano de Buenos Aires. maria.posadas@hiba.org.ar. 6. Imtib y Servicio de Clínica médica del Hospital Italiano de Bs As.. adela.aguirre@hiba.org.ar. 7. Hospital Italiano de Buenos Aires.. elsa.nucifora@hiba.org.ar.
Abstract
The increasing complexity in the approach to diseases challenges the development of a new paradigm of care that crosses disciplinary limits, where professionals from different disciplines approach a problem applying their expertise, respecting the knowledge of the other and contributing to the global view of the problem. Amyloidoses are rare diseases. The diagnosis is based on the biopsy of those organs in which amyloid infiltration is suspected. There is an increased risk of bleeding associated with these procedures. Therefore, the availability of obtaining samples from certain sites with less invasive accesses, such as the minor salivary glands (GSM), represent an alternative. Objectives: Describe the experiences of GSM biopsies as a diagnostic tool in the detection of amyloidosis and its intra and postoperative complications. - Estimate the diagnostic performance. The design is a cross-sectional cohort. All patients with a suspected diagnosis of amyloidosis were consecutively included, between August 2018-September 2020. Results: 23 biopsies were performed with minimally invasive procedures. 60.86% were male and the average age was 66 years. The prevalence of amyloidosis was 33%. The sensitivity was 55% and the specificity 100%. One patient had more bleeding than usual during the procedure and none had postoperative complications. Conclusions: GSM biopsy experiences were described as a diagnostic tool for amyloidosis, reporting a slight intraoperative complication and no postoperative complication. The test achieved a sensitivity of 55% and a specificity of 100%. Universidad Nacional de Córdoba
The increasing complexity in the approach to diseases challenges the development of a new paradigm of care that crosses disciplinary limits, where professionals from different disciplines approach a problem applying their expertise, respecting the knowledge of the other and contributing to the global view of the problem. Amyloidoses are rare diseases. The diagnosis is based on the biopsy of those organs in which amyloid infiltration is suspected. There is an increased risk of bleeding associated with these procedures. Therefore, the availability of obtaining samples from certain sites with less invasive accesses, such as the minor salivary glands (GSM), represent an alternative. Objectives: Describe the experiences of GSM biopsies as a diagnostic tool in the detection of amyloidosis and its intra and postoperative complications. - Estimate the diagnostic performance. The design is a cross-sectional cohort. All patients with a suspected diagnosis of amyloidosis were consecutively included, between August 2018-September 2020. Results: 23 biopsies were performed with minimally invasive procedures. 60.86% were male and the average age was 66 years. The prevalence of amyloidosis was 33%. The sensitivity was 55% and the specificity 100%. One patient had more bleeding than usual during the procedure and none had postoperative complications. Conclusions: GSM biopsy experiences were described as a diagnostic tool for amyloidosis, reporting a slight intraoperative complication and no postoperative complication. The test achieved a sensitivity of 55% and a specificity of 100%. Universidad Nacional de Córdoba
Authors: María Lida Santiago; María Renata Seisdedos; Rodrigo Nicolás García Salinas; Anastasia Secco; Lucila Marino Claverie; Lorena Techera; Lorena Takashima; Pedro Aicardi; Marco Antonio Sandi Rosales; Elizabeth Knobel; Sebastián Juan Magri; Antonio Carlos Catalán Pellet Journal: Reumatol Clin Date: 2012-07-06
Authors: Jean D Sipe; Merrill D Benson; Joel N Buxbaum; Shu-ichi Ikeda; Giampaolo Merlini; Maria J M Saraiva; Per Westermark Journal: Amyloid Date: 2014-09-29 Impact factor: 7.141
Authors: Morie A Gertz; Ray Comenzo; Rodney H Falk; Jean Paul Fermand; Bouke P Hazenberg; Philip N Hawkins; Giampaolo Merlini; Philippe Moreau; Pierre Ronco; Vaishali Sanchorawala; Orhan Sezer; Alan Solomon; Giles Grateau Journal: Am J Hematol Date: 2005-08 Impact factor: 10.047
Authors: María Adela Aguirre; Bruno Rafael Boietti; Elsa Nucifora; Patricia Beatriz Sorroche; Fernán González Bernaldo de Quirós; Diego Hernan Giunta; María Lourdes Posadas-Martínez Journal: Amyloid Date: 2016-07-28 Impact factor: 7.141
Authors: Fernanda de Paula Eduardo; Letícia de Mello Bezinelli; Danielle Lima Corrêa de Carvalho; Bianca Della-Guardia; Marcio Dias de Almeida; Lidiane Vieira Marins; Luciana Corrêa Journal: Neurol Sci Date: 2016-11-15 Impact factor: 3.307
Authors: Helen J Lachmann; David R Booth; Susanne E Booth; Alison Bybee; Janet A Gilbertson; Julian D Gillmore; Mark B Pepys; Philip N Hawkins Journal: N Engl J Med Date: 2002-06-06 Impact factor: 91.245
Authors: Sandra M Soares; Fernando C Fervenza; Donna J Lager; Morie A Gertz; Fernando G Cosio; Nelson Leung Journal: Am J Kidney Dis Date: 2008-07-23 Impact factor: 8.860
Authors: Jennifer H Pinney; Colette J Smith; Jessi B Taube; Helen J Lachmann; Christopher P Venner; Simon D J Gibbs; Jason Dungu; Sanjay M Banypersad; Ashutosh D Wechalekar; Carol J Whelan; Philip N Hawkins; Julian D Gillmore Journal: Br J Haematol Date: 2013-03-11 Impact factor: 6.998